GLP-1 Treatment Tracker: How to Monitor Your Weight Loss Progress
Build an effective GLP-1 treatment tracking system. Learn what metrics to monitor, how often to check in, and how to know if semaglutide or tirzepatide is working.
More on Monitoring
Why Tracking Matters
Patients who systematically track their GLP-1 treatment see 30% better outcomes on average. A treatment tracker helps you and your provider make informed dose adjustments and catch potential issues early.
Essential Metrics to Track
Whether you're on semaglutide ($99/mo) or tirzepatide ($125/mo), tracking these key metrics will help you optimize your treatment and stay accountable.
Weekly Measurements
- Body weight (same time, same conditions)
- Waist circumference at navel
- Progress photos (front, side, back)
- Appetite level (1-10 scale)
Daily Notes
- Side effects and severity
- Energy levels throughout the day
- Food intake and water consumption
- Sleep quality and duration
Tracking Timeline by Treatment Phase
Weeks 1-4: Baseline Phase
Record your starting weight, measurements, and baseline lab values. Track side effects carefully as your body adjusts. Most patients start at the lowest dose during this period.
Months 2-3: Titration Phase
Doses typically increase every 4 weeks. Track how each dose change affects appetite, side effects, and weight loss rate. This data helps your provider find your optimal dose.
Months 4-6: Active Loss Phase
You should see consistent weight loss of 1-2 lbs per week. Track body composition changes -- you may lose inches even during weeks the scale doesn't move.
Months 6-12+: Optimization Phase
Weight loss may slow as you approach your goal. Shift tracking focus to body composition, fitness improvements, and metabolic health markers like blood pressure and A1c.
Building Your Tracking System
Choose a method that fits your lifestyle. Consistency matters more than complexity.
What Your Data Tells You
Steady 1-2 lb/week loss
Your treatment is working well. Continue current dose and habits.
Plateau for 3+ weeks
May indicate need for dose adjustment, dietary changes, or increased activity. Discuss with your provider.
Rapid loss (3+ lbs/week consistently)
May be too fast -- could indicate muscle loss or inadequate nutrition. Ensure protein intake is adequate and consider slowing the titration schedule.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your treatment plan. Individual results vary.
Frequently Asked Questions
How often should I track my weight on GLP-1 medication?
Weigh yourself once per week at the same time, ideally in the morning before eating. Daily weigh-ins can be misleading due to water fluctuations. Weekly tracking gives you a more accurate picture of your progress on semaglutide or tirzepatide.
What should I track besides weight?
Track body measurements (waist, hips, arms), energy levels, appetite changes, side effects, sleep quality, mood, and blood pressure. Many patients lose inches before the scale moves significantly, especially in the first few weeks.
What's a good rate of weight loss on GLP-1 medications?
Most patients lose 1-2 pounds per week on semaglutide or tirzepatide. During dose titration, weight loss may be slower. The average total weight loss is 15-20% of body weight over 12-18 months.
Should I use an app to track my GLP-1 treatment?
Yes, a tracking app or journal can help you identify patterns, share progress with your provider, and stay motivated. Record your injection dates, doses, side effects, meals, and measurements in one place.
Start Your GLP-1 Weight Loss Journey
Compounded semaglutide from $99/mo or tirzepatide from $125/mo. Includes provider consultations and ongoing support.
View Treatment OptionsSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).